Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

IL-4 and IFN-γ as Immunologic Predictors of Response to HPV Immunotherapy in Warts

ID
Name
3140-23-10-2019
Description
In the present study the investigators assessed the invitro role of IL-4 and IFN-γ in predicting the response to bivalent HPV vaccine after whole blood stimulation
Trial arms
Trial start
2020-01-03
Estimated PCD
2020-07-03
Trial end
2021-03-02
Status
Completed
Treatment
IL-4 and IFN-γ measurements
Blood samples are withdrawn from participants and whole blood cultures are prepared and stimulated by bivalent HPV vaccine.IL-4 and IFN-γ are measured in culture supernatants
Arms:
Cases, Controls
Size
80
Primary endpoint
Change of IFN-γ and IL-4 levels
48 hours
Eligibility criteria
Inclusion Criteria: * Patients with recurrent and recalcitrant cutaneous and anogenital warts. Exclusion Criteria: * History of allergy to the HPV vaccine * Active viral, fungal, or bacterial infections * Immunosuppressive diseases or drugs. * Autoimmune diseases, or other systemic diseases, e.g., hepatic, or renal disorders, diabetes, meningitis or convulsions * Skin allergies * Pregnancy and lactation * Earlier wart treatment at least one month before enrollment.
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 80, 'type': 'ACTUAL'}}
Updated at
2023-11-14

1 organization

1 product

3 indications

Organization
Zagazig University
Product
IL-4 and IFN-γ measurements
Indication
Warts on Hand
Indication
Wart
Indication
Genital